Showing results (101-110 of 129) with videos related to
Sort By:
Pageof 13
Lancet (London, England)|June 2, 2018
Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trialDrew J Winston, Kathleen M Mullane, Oliver A Cornely, et al.The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative GroupKarl Sotlar, Tracy I George, Philip Kluin, et al.Clinical Pharmacology and Therapeutics|January 20, 2023
Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 InhibitorsJun-Ichi Nishimura, Antoine Soubret, Noriko Arase, et al.Blood|January 25, 2020
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuriaAlexander Röth, Jun-Ichi Nishimura, Zsolt Nagy, et al.The Journal of Investigative Dermatology|February 13, 2021
Clinical Impact of Skin Lesions in Mastocytosis: A Multicenter Study of the European Competence Network on MastocytosisElisabeth Aberer, Wolfgang R Sperr, Agnes Bretterklieber, et al.Blood|January 29, 2021
Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosisMarcelo A S Toledo, Malrun Gatz, Stephanie Sontag, et al.Journal of the American Academy of Dermatology|February 14, 2026
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER studyFrank Siebenhaar, Sigurd Broesby-Olsen, Mariana Castells, et al.Hemasphere|June 8, 2026
Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapyAustin Kulasekararaj, Flore S de Fontbrune, Anna Gaya, et al.The Lancet. Haematology|May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trialAndrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2020
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of ImmunotherapyAnna Kron, Matthias Scheffler, Carina Heydt, et al.Pageof 13